Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Dec 21, 2017 (9 years ago)

Clobetasol Propionate Cream USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Content Uniformity Specifications

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Clobetasol Propionate Cream USP, 0.05% 60 g tube, Rx only Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761 Dist. by : Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532 UPC 351672125837 NDC 51672-1258-3

Affected NDC 51672-1258-03

Compare with the code on your package — it is the most precise check available.

Drug: Clobetasol

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Clobetasol Propionate
NDC 51672-1258
.5 mg/g Cream
Topical
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Taro Pharmaceuticals U.S.A., Inc.
NDC code
51672-1258-3
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0249-2018 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Clobetasol recalls

See all

Other recalls by Taro Pharmaceuticals U.S.A., Inc.

All 2017 recalls
Class III · Low risk

Hydrocortisone 1% & Acetic Acid 2% Otic Solution

Failed Impurities/Degradation Specifications: Out-of-specification results obtained for related impurities and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing.

Completed Impurity / degradation Taro Pharmaceuticals U.S.A., Inc. NDC 51672-3007-01 D-0633-2024